| Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity M Soethoudt, U Grether, J Fingerle, TW Grim, F Fezza, L De Petrocellis, ... Nature communications 8 (1), 13958, 2017 | 314 | 2017 |
| Uncoupling DNA damage from chromatin damage to detoxify doxorubicin X Qiao, SY van der Zanden, DPA Wander, DM Borràs, JY Song, X Li, ... Proceedings of the National Academy of Sciences 117 (26), 15182-15192, 2020 | 125 | 2020 |
| Structural basis of ligand interaction with atypical chemokine receptor 3 M Gustavsson, L Wang, N Van Gils, BS Stephens, P Zhang, TJ Schall, ... Nature communications 8 (1), 14135, 2017 | 108 | 2017 |
| The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI‐101 prevents cisplatin‐induced nephrotoxicity P Mukhopadhyay, M Baggelaar, K Erdelyi, Z Cao, R Cinar, F Fezza, ... British journal of pharmacology 173 (3), 446-458, 2016 | 78 | 2016 |
| Escape from treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia N Van Gils, F Denkers, L Smit Frontiers in oncology 11, 659253, 2021 | 74 | 2021 |
| Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation N van Gils, HJMP Verhagen, L Smit Experimental hematology 52, 12-23, 2017 | 47 | 2017 |
| IGFBP7 induces differentiation and loss of survival of human acute myeloid leukemia stem cells without affecting normal hematopoiesis HJMP Verhagen, N van Gils, T Martiañez, A van Rhenen, A Rutten, ... Cell reports 25 (11), 3021-3035. e5, 2018 | 19 | 2018 |
| The novel oral BET-CBP/p300 dual inhibitor NEO2734 is highly effective in eradicating acute myeloid leukemia blasts and stem/progenitor cells N van Gils, TM Canales, E Vermue, A Rutten, F Denkers, T van der Deure, ... Hemasphere 5 (8), e610, 2021 | 13 | 2021 |
| Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors M Soethoudt, N van Gils, M van der Stelt, LH Heitman Endocannabinoid Signaling: Methods and Protocols, 103-111, 2016 | 11 | 2016 |
| Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat Commun 8: 13958 M Soethoudt, U Grether, J Fingerle, TW Grim, F Fezza, L De Petrocellis, ... | 9 | 2017 |
| Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression MF van Spronsen, D Hanekamp, TM Westers, N van Gils, E Vermue, ... leukemia 37 (3), 680-690, 2023 | 8 | 2023 |
| IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells N van Gils, HJMP Verhagen, A Rutten, RX Menezes, ML Tsui, E Vermue, ... Blood advances 4 (24), 6368-6383, 2020 | 6 | 2020 |
| Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat Commun. 2017; 8: 13958 M Soethoudt, U Grether, J Fingerle, TW Grim, F Fezza, L De Petrocellis, ... PubMed: https://pubmed. ncbi. nlm. nih. gov/28045021, 0 | 6 | |
| Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters N van Gils, HJMP Verhagen, M Broux, T Martiáñez, F Denkers, E Vermue, ... Iscience 25 (9), 2022 | 5 | 2022 |
| Cellular assay to study β-arrestin recruitment by the cannabinoid receptors 1 and 2 J Bouma, M Soethoudt, N van Gils, L Xia, M van der Stelt, LH Heitman Endocannabinoid Signaling: Methods and Protocols, 189-199, 2022 | 4 | 2022 |
| Dual Split-Signaling TIM3+ CLEC12a targeting CAR T-Cells with Optimized Signaling as a safe potential therapy for Acute myeloid leukemia JJ Van Der Schans, P Vishwasrao, N Van Gils, M Hosny, Z Wang, ... Blood 142, 883, 2023 | 1 | 2023 |
| PS967 PRECLINICAL ACTIVITY OF THE NOVEL ORAL DUAL BET-CBP/P300 INHIBITORS, NEO1132 AND NEO2734, IN ACUTE MYELOID LEUKEMIA TM Canales, N van Gils, E Vermue, A Rutten, F Denkers, T van der Deure, ... HemaSphere 3 (S1), 435-436, 2019 | 1 | 2019 |
| IDENTIFICATION OF THERAPEUTIC STRATEGIES DIRECTED TO ACUTE MYELOID LEUKEMIA MINIMAL RESIDUAL DISEASE N van Gils, FL Kessler, M Broux, F Denkers, A Rutten, S Demeyer, J Cools, ... ANNALS OF HEMATOLOGY 102 (SUPPL 1), S58-S58, 2023 | | 2023 |
| Therapeutic target identification and drug-target validation for acute myeloid leukemia N van Gils | | 2022 |
| P462: IDENTIFICATION OF TARGETED THERAPIES DIRECTED TO ACUTE MYELOID LEUKEMIA MINIMAL RESIDUAL DISEASE N van Gils, F Kessler, M Broux, F Denkers, S Demeyer, J Cools, ... HemaSphere 6, 361-362, 2022 | | 2022 |
